Corrigendum to "Pyridone derivatives as potent and selective VLA-4 integrin antagonists" [Bioorg. Med. Chem. Lett. 16 (2006) 2256-2259] (DOI:10.1016/j.bmcl.2006.01.025);Pyridone derivatives as potent and selective VLA-4 integrin antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 8, 2006, Pages 2256-2259

  Witherington, Jason ^a   Bordas, Vincent ^a   Gaiba, Alessandra ^a   Green, Phil M ^b   Naylor, Antoinette ^a   Parr, Nigel ^c   Smith, David G ^a   Takle, Andrew K ^a   Ward, Robert W ^a  

^a Glaxo Smith Kline   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Cell Biology Unit   (United Kingdom)

Author keywords

GASP; Molecular overlays; Pharmacophore; Pyridone; Ureas; VLA 4

Indexed keywords

INTEGRIN; INTEGRIN RECEPTOR; PYRIDONE DERIVATIVE; VERY LATE ACTIVATION ANTIGEN 4;

ARTICLE; DIAGNOSIS RELATED GROUP; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HYDROLYSIS KINETICS; OXIDATION KINETICS; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

EID: 33644806005     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.03.039     Document Type: Erratum

References (20)

1. M.E. Helmer, M.J. Elices, C. Parker, and Y. Takada Immunol. Rev. 114 1990 45
2. T.A. Springer Cell 76 1994 301
3. M.J. Elices Curr. Opin. Anti-inflam. Immunomod. Investig. Drugs 1 1999 14
4. A.J.H. Gearing, and W. Newman Immunol. Today 14 1993 506
5. M.E. Helmer Annu. Rev. Immunol. 8 1990 365
6. K.-C. Lin, H.S. Ateeq, S.H. Hsiung, L.T. Chong, C.N. Zimmerman, A. Castro, W.-C. Lee, C.E. Hammond, S. Kalkunte, L.-L. Chen, R.B. Pepinsky, D.R. Leone, A.G. Sprague, W.M. Abraham, A. Gill, R.A. Lobb, and S.P. Adams J. Med. Chem. 42 1999 920
7. K.-C. Lin, and A.C. Castro Curr. Opin. Chem. Biol. 2 1998 453
8. D. Seiffge J. Rheumatol. 23 1996 2086
9. N. Tubridy, P.O. Behan, R. Caplildeo, A. Chaudhuri, R. Forbes, C.P. Hawkins, R.A.C. Hughes, J. Palace, B. Sharrack, R. Swingler, C. Young, I.F. Mosley, D.G. MacManus, S. Donoghue, and D.H. Miller Neurology 53 1999 466
10. E. Keszthelyi, S. Karlik, S. Hyduk, A. Rice, G. Gordon, T. Yednock, and H. Horner Neurology 47 1996 1053
11. D.K. Podolsky, R. Lobb, N. King, C.D. Benjamin, B. Pepinsky, P. Sehgal, and M. deBaumont J. Clin. Invest. 92 1993 972
12. B. Cannella, S. Gaupp, R.G. Tilton, and C.S. Raine J. Neurosci. Res. 71 2003 407
13. i. Standard compound A is (2S)-3-[4-({[4-(aminocarbonyl)- 1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy) acetyl]amino}pentanoyl)amino] propanoic acid potassium salt which is described in patent application WO 00/37444. Compounds were assayed in duplicate, a four-parameter curve fit being applied. The equilibrium dissociation constant for each compound was calculated according to the method of Cheng and Prusoff (Biochem. Pharmacol. 1973, 22, 3099).
14. Astles, P. C.; Clark, D. E.; Collis, A. J.; Cox, P. J.; Eastwood, P. J.; Harris, N. V.; Lai, J. Y. Q.; Morley, A. D.; Porter, B. WO 992306.
15. J. Singh, H.V. Vlihmen, Y. Liao, W.-C. Lee, M. Corbenise, M. Harris, I.-H. Shu, A. Gill, J.H. Cuervo, W.M. Abraham, and S.P. Adams J. Med. Chem. 45 2002 2988
16. CEREP Poitiers, Le Bois l'Evêque, B.P.186 600 Celle l'Evescault, FRANCE.
17. Witherington, J; Elliot, R. L. JP 2005255675.
18. Witherington, J; Elliot, R. L. WO 2004014859.
19. M. Ishikura, M. Kamada, and M. Terashima Heterocycles 22 1984 265
20. Fukuda, Y.; Chujo, I.; Fuchikami, T.; Hirosawa, C.; Wakasa, N. WO 97/47581.